Amicus Therapeut Stock Price, News & Analysis

Amicus Therapeutics (Nasdaq: FOLD) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference, scheduled for September 14, 2022, at 12:20 p.m. E.T. in New York City. The event will be accessible via a live audio webcast on the company’s investor relations website. Amicus Therapeutics focuses on developing innovative therapies for rare metabolic diseases, emphasizing high-quality patient care and a commitment to expanding its pipeline of medicines.

Amicus Therapeutics (Nasdaq: FOLD) reported Galafold revenue of $159.4 million for H1 2022, showing an 11% increase year-over-year, driven by 18% operational growth, despite a 7% currency impact. The company anticipates a full-year revenue growth of 15-20% at constant exchange rates. Key regulatory reviews for AT-GAA are advancing, with FDA action dates set for August 29 and October 29, 2022. Amicus has strengthened its patent portfolio with 17 new U.S. patents and aims for non-GAAP profitability by 2023. Cash reserves stood at $386.8 million as of June 30, 2022.

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on August 4, 2022, at 8:30 a.m. ET to discuss its financial results for Q2 2022, which ended on June 30, 2022. Participants can access the call by dialing 1-833-634-2601 or 1-412-902-4113 for international callers. A live audio webcast will also be available on the company's investor website. A replay will be accessible for seven days following the event. Amicus focuses on developing therapies for rare metabolic diseases and has a commitment to a robust pipeline of innovative medicines.

Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 11:20 a.m. P.T. The event will be held in Rancho Palos Verdes, CA. Investors can access a live audio webcast of the presentation on the company's investor relations website. Amicus focuses on developing innovative medicines for rare metabolic diseases, showcasing its commitment to patient-centered care and a robust pipeline of novel treatments.

Amicus Therapeutics (Nasdaq: FOLD) announced a 90-day extension to the FDA review period for the Biologics License Application (BLA) of cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, both components of AT-GAA. The new action dates are August 29, 2022, and October 29, 2022, respectively. This extension allows additional time for the FDA to review submitted information and to complete pre-license inspections at the manufacturing site. The company remains optimistic about FDA approval for AT-GAA as a treatment for Pompe disease.

Amicus Therapeutics reported a strong first quarter of 2022, with Galafold® revenue reaching $78.7 million, an 18.5% year-over-year increase. The company strengthened its intellectual property with new patents extending protection through 2038. Regulatory reviews for AT-GAA in Pompe Disease are progressing, with the FDA's action dates set for May 29 and July 29, 2022. Amicus anticipates continued double-digit growth for Galafold, projecting $350 million to $365 million in revenue for the year. However, the net loss for the quarter was $85.3 million.

Amicus Therapeutics (Nasdaq: FOLD) announced participation in a fireside chat at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 12:00 p.m. P.T. The event will take place in Las Vegas, NV. A live audio webcast will be available on the company's investor website. Amicus Therapeutics is dedicated to developing novel therapies for rare metabolic diseases, focusing on patient needs and advancing a robust pipeline of innovative medicines. For further details, visit their website or access the webcast.

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call and live audio webcast on May 9, 2022, at 8:30 a.m. ET to discuss financial results for Q1 2022, covering the period ended March 31, 2022. Investors can participate by calling 877-303-5859 (U.S./Canada) or 678-224-7784 (international) and using conference ID 7867383. Additionally, a replay will be available for seven days post-call. The company focuses on developing innovative therapies for rare metabolic diseases and is dedicated to patient-centric care. For further information, visit their corporate website.